Progress in study on the association between HLA genetic variation and adverse drug reactions.
10.11817/j.issn.1672-7347.2021.200256
- Author:
Yating LIU
1
;
Xiangchang ZENG
2
;
Dongsheng OUYANG
3
Author Information
1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008. 188111105@csu.edu.cn.
2. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008.
3. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008. 801940@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
adverse drug reaction;
genetic polymorphism;
human leukocyte antigen;
immunity
- MeSH:
Drug-Related Side Effects and Adverse Reactions/genetics*;
Genotype;
HLA Antigens/genetics*;
Humans;
Polymorphism, Genetic
- From:
Journal of Central South University(Medical Sciences)
2021;46(4):404-413
- CountryChina
- Language:English
-
Abstract:
The human leukocyte antigen (HLA) molecules encoded within the human major histocompatibility complex are a group of highly conserved cell surface proteins, which are related to antigen recognition. HLA genes display a high degree of genetic polymorphism, which is the basis of individual differences in immunity. Specific HLA genotypes have been highly associated with typical adverse drug reactions. HLA-A*31:01 and HLA-B*15:02 are associated with carbamazepine-induced severe cutaneous adverse reactions, HLA-B*57:01 is related to abacavir-induced drug-induced hypersensitivity syndrome and flucloxacillin/pazopanib-induced drug-induced liver injury, while HLA-B*35:01 is a potential biomarker for predicting polygonum multiflorum-induced liver injury. It is not clear how small drug molecules to interact with HLA molecules and T cell receptors (TCR). There are four mechanistic hypotheses, including the hapten/prohapten theory, the pharmacological interaction concept, the altered peptide repertoire model, and the altered TCR repertoire model.
